(Q37607731)

21 August 2017

1 reference

title

Prevention and management of stroke in very elderly patients (English)

1 reference

21 August 2017

0 references

2

Bruce Ovbiagele

1 reference

21 August 2017

Nerses Sanossian

1

1 reference

21 August 2017

language of work or name

1 reference

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1031-1041

1 reference

Treatment of hypertension in patients 80 years of age or older

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Counci

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population-based cross-sectional survey in Helsinki, Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Treatment for the secondary prevention of stroke in older patients: the influence of dementia status

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Stroke Outcome in Those Over 80

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitat

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Clinical correlates and drug treatment of residents with stroke in long-term care

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Prescription of antithrombotic therapy in older patients hospitalized for transient ischemic attack and ischemic stroke: the GIFA study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Guidelines for the Early Management of Adults With Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Blood pressure control in patients initiating antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

International Society of Hypertension (ISH)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Beta-blockers as fourth-line therapy for hypertension: stay the course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Antihypertensive treatment in elderly hypertensives without a history of stroke and the risk of cognitive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Blood pressure and survival in the oldest old.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

High-density lipoprotein cholesterol: an emerging target for stroke treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

The challenges of clinical trials in the exclusion zone: the case of the frail elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Biological basis for statin therapy in stroke prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Vascular effects of statins in stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Statins in stroke: prevention, protection and recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Statins, low-density lipoprotein cholesterol, and risk of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Primary prevention of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Antiplatelet treatment in elderly people with transient ischaemic attacks or ischaemic strokes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Do all age groups benefit from organized inpatient stroke care?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Number Needed to Treat Estimates Incorporating Effects Over the Entire Range of Clinical Outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Acute stroke management in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age--a systematic review across cohort studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Stroke thrombolysis in the elderly: risk or benefit?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Predictors of cerebral microbleeds in acute ischemic stroke and TIA patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Cerebral white matter hyperintensities on MRI: Current concepts and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Leukoaraiosis Is a Risk Factor for Symptomatic Intracerebral Hemorrhage After Thrombolysis for Acute Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970259-5

7 January 2021

10.1016/S1474-4422(09)70259-5

Identifiers

DOI

1 reference

21 August 2017

1 reference